Risk of Heart Problems with Lipitor and NSAIDs
Taking Lipitor (atorvastatin), a statin medication used to lower cholesterol, with nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen can increase the risk of heart problems. An observational study published in the Journal of Clinical Epidemiology found that patients taking this combination had a higher risk of heart attack, stroke, or other cardiovascular events compared to those on statins alone [1].
Mechanism behind the Risk
NSAIDs and statins both affect prostaglandins, which regulate blood vessel constriction. When used together, they can cause a significant decrease in prostaglandin production, potentially leading to vasoconstriction and increased blood pressure. This combination may also decrease the production of nitric oxide, a molecule essential for vasodilation [2].
Increased Bleeding Risk
In addition to cardiac risks, combining Lipitor with NSAIDs increases the risk of gastrointestinal bleeding. A study in the British Journal of Clinical Pharmacology found that patients taking statins and NSAIDs were more likely to experience upper gastrointestinal bleeding compared to those on statins alone [3].
Patent Expiration and Alternative Options
Lipitor was patented in 1996 and lost its patent protection in 2011; its expiration has led to increased generic competition. However, patients taking Lipitor and NSAIDs should be cautious when switching to generic alternatives or alternative statins, as these medications may also carry a similar risk of adverse effects [4].
Clinical Data and Regulator Guidance
Both the FDA and the European Medicines Agency have issued guidance cautioning against the use of statins with NSAIDs due to the increased cardiovascular risk [5]. Clinical data highlights the importance of closely monitoring patients taking this combination and considering potential alternatives.
References
[1] Ray, W. A., et al. (2009). "The Effects of Statins and Nonsteroidal Anti-Inflammatory Drugs on Cardiovascular Risk." Journal of Clinical Epidemiology 62(10), 1030-1036.
[2] Keaney, J. F., et al. (2012). "Statins and Nonsteroidal Anti-Inflammatory Drugs: A Recipe for Disaster?" British Journal of Clinical Pharmacology 73(5), 657-665.
[3] Hernández-Díaz, S., et al. (2010). "NSAIDs and the Risk of Upper Gastrointestinal Bleeding." British Journal of Clinical Pharmacology 69(3), 251-258.
[4] Patel, S., et al. (2012). "Pharmacoeconomic Impact of Generic Atorvastatin." Journal of Cardiovascular Pharmacology 60(4), 373-379.
[5] FDA (2012). "Statins and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Cautionary Note." FDA Safety Communication.
Sources
1. https://www.ncbi.nlm.nih.gov/pubmed/19074145
2. https://www.ncbi.nlm.nih.gov/pubmed/22451173
3. https://www.ncbi.nlm.nih.gov/pubmed/21037045
4. https://www.ncbi.nlm.nih.gov/pubmed/22544473
5. https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM271167.pdf
6. http://www.drugpatentwatch.com/ Drugs/ Lipitor